Symbiotec Pharmalab sets ₹1757 crore IPO price band at ₹938-₹988 per share
Symbiotec Pharmalab will open its ₹1,757 crore IPO on August 24, with a price band of ₹938-₹988 per share and bidding closing on August 27.
From left to right: Shubham Saboo, General Manager, CMD Office; Raghavender Ramachandran, Chief Financial Officer; Anil Satwani, Chairman and Managing Director, Symbiotec Pharmalab Limited; Kashish Satwani, Promoter; Krishna Satwani, Head – BD Injectable; and Kapil Mishra, Head – Strategy, CMD Office, Symbiotec Pharmalab Limited, at the company’s press conference.
MUMBAI: Symbiotec Pharmalab Limited will open its ₹1,757 crore Initial Public Offer (IPO) on August 24, 2026, with the price band fixed at ₹938 to ₹988 per equity share of face value ₹2.
The IPO will comprise a fresh issue of equity shares aggregating up to ₹150 crore and an offer for sale of shares worth up to ₹1,607 crore by existing shareholders. The company plans to use the net proceeds from the fresh issue towards prepayment and/or repayment of certain outstanding borrowings and general corporate purposes.
The IPO will open for subscription on Monday, August 24, and close on Thursday, August 27. The anchor investor bidding period will be held on August 21. Investors can bid for a minimum of 15 equity shares and in multiples of 15 shares thereafter. Eligible employees will be offered a discount of ₹90 per equity share under the employee reservation portion.
The offer for sale includes shares worth up to ₹144 crore from promoter selling shareholder Satwani Holdings LLP, ₹988 crore from Rosewood Investments and ₹475 crore from India Business Excellence Fund – III.
The equity shares are proposed to be listed on BSE Limited and the National Stock Exchange of India Limited, with BSE designated as the stock exchange for the offer. The Red Herring Prospectus was filed with the Registrar of Companies, Madhya Pradesh at Gwalior, on August 18, 2026.
JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory and Securities (India) are the bookrunning lead managers for the offer.
The IPO will be conducted through the book-building process. Up to 50% of the net offer will be available for allocation to Qualified Institutional Buyers, while not less than 15% will be available for Non-Institutional Bidders and not less than 35% for Retail Individual Bidders, subject to the applicable regulatory provisions.
All bidders other than anchor investors are required to participate through the Application Supported by Blocked Amount (ASBA) process, with UPI applicable to eligible UPI bidders.
The company has cautioned prospective investors that investment in equity shares involves a high degree of risk and advised them to refer to the Risk Factors section of the Red Herring Prospectus before making investment decisions.
